{"id":"https://openalex.org/W4362624580","doi":"https://doi.org/10.1158/1535-7163.22519549.v1","title":"Figure S2 from Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity","display_name":"Figure S2 from Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362624580","doi":"https://doi.org/10.1158/1535-7163.22519549.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22519549.v1","doi":"https://doi.org/10.1158/1535-7163.22519549.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22519549.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Site-Specific_PEGylation_of_Anti-Mesothelin_Recombinant_Immunotoxins_Increases_Half-life_and_Antitumor_Activity/22519549/1/files/39982174.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Site-Specific_PEGylation_of_Anti-Mesothelin_Recombinant_Immunotoxins_Increases_Half-life_and_Antitumor_Activity/22519549/1/files/39982174.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069928382","display_name":"Zeliang Zheng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zeliang Zheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042339519","display_name":"Ryuhei Okada","orcid":"https://orcid.org/0000-0003-3589-5054","observed_orcids":["https://orcid.org/0000-0003-3589-5054"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryuhei Okada","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3589-5054","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090173640","display_name":"Hisataka Kobayashi","orcid":"https://orcid.org/0000-0003-1019-4112","observed_orcids":["https://orcid.org/0000-0003-1019-4112"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hisataka Kobayashi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075595526","display_name":"Tadanobu Nagaya","orcid":"https://orcid.org/0000-0002-0091-8343","observed_orcids":["https://orcid.org/0000-0002-0091-8343"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tadanobu Nagaya","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005008349","display_name":"Junxia Wei","orcid":"https://orcid.org/0009-0009-8366-4657","observed_orcids":["https://orcid.org/0009-0009-8366-4657"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Junxia Wei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Qi Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qi Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101398908","display_name":"Fred Lee","orcid":"https://orcid.org/0000-0003-1275-5497","observed_orcids":["https://orcid.org/0000-0003-1275-5497"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fred Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002583441","display_name":"Tapan Kumar Bera","orcid":"https://orcid.org/0000-0002-8779-4004","observed_orcids":["https://orcid.org/0000-0002-8779-4004"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tapan K. Bera","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015906742","display_name":"Yun Liang Gao","orcid":"https://orcid.org/0000-0002-9898-5690","observed_orcids":["https://orcid.org/0000-0002-9898-5690","https://orcid.org/0000-0002-9694-0907","https://orcid.org/0000-0002-3012-0340"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yun Gao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052483257","display_name":"William A. Kuhlman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Kuhlman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076748687","display_name":"Chin\u2010Hsien Tai","orcid":"https://orcid.org/0000-0003-4766-0535","observed_orcids":["https://orcid.org/0000-0003-4766-0535"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chin-Hsien Tai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5056573254","display_name":"Ira H Pastan","orcid":"https://orcid.org/0000-0002-9223-0270","observed_orcids":["https://orcid.org/0000-0002-9223-0270"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ira Pastan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9223-0270","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mesothelin","display_name":"mesothelin","score":0.8450000286102295},{"id":"https://openalex.org/keywords/pegylation","display_name":"PEGylation","score":0.9049999713897705},{"id":"https://openalex.org/keywords/recombinant-immunotoxin","display_name":"recombinant immunotoxin","score":0.9900000095367432},{"id":"https://openalex.org/keywords/site-specific-pegylation","display_name":"site-specific PEGylation","score":0.7400000095367432},{"id":"https://openalex.org/keywords/half-life","display_name":"half-life","score":0.675000011920929},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9980000257492065}],"concepts":[{"id":"https://openalex.org/C2777045440","wikidata":"https://www.wikidata.org/wiki/Q14914057","display_name":"Mesothelin","level":3,"score":0.9800926446914673},{"id":"https://openalex.org/C2779149719","wikidata":"https://www.wikidata.org/wiki/Q682252","display_name":"PEGylation","level":3,"score":0.9225404262542725},{"id":"https://openalex.org/C115085202","wikidata":"https://www.wikidata.org/wiki/Q425665","display_name":"Immunotoxin","level":4,"score":0.8634915351867676},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.8148945569992065},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49187779426574707},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.43247461318969727},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37970247864723206},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2437727153301239},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.22481957077980042},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16076669096946716},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.11954104900360107},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.10949823260307312},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.10596457123756409},{"id":"https://openalex.org/C2776964284","wikidata":"https://www.wikidata.org/wiki/Q410083","display_name":"Polyethylene glycol","level":2,"score":0.06736549735069275},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.05456262826919556}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.22519549.v1","doi":"https://doi.org/10.1158/1535-7163.22519549.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22519549.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Site-Specific_PEGylation_of_Anti-Mesothelin_Recombinant_Immunotoxins_Increases_Half-life_and_Antitumor_Activity/22519549/1/files/39982174.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22519549","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Figure_S2_from_Site-Specific_PEGylation_of_Anti-Mesothelin_Recombinant_Immunotoxins_Increases_Half-life_and_Antitumor_Activity/22519549","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22519549.v1","doi":"https://doi.org/10.1158/1535-7163.22519549.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22519549.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Site-Specific_PEGylation_of_Anti-Mesothelin_Recombinant_Immunotoxins_Increases_Half-life_and_Antitumor_Activity/22519549/1/files/39982174.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4362624580.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362624793","https://openalex.org/W4362638121","https://openalex.org/W4362614468","https://openalex.org/W4362614229","https://openalex.org/W4392701640","https://openalex.org/W2997388109","https://openalex.org/W4362635872","https://openalex.org/W2020169547","https://openalex.org/W1990761369","https://openalex.org/W4362492615"],"abstract_inverted_index":{"Mesothelin":[0],"binding":[1],"of":[2],"PEGylated":[3],"RITs":[4]},"counts_by_year":[],"updated_date":"2026-10-06T10:28:23.643775","created_date":"2023-04-07T00:00:00"}